DataMEDS AI, Inc.

• Third quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the second quarter of 2026, primarily driven by growth in Corexa Pharmacy drug dispensing
• Launch of the Health Lives Here mobile app, partnered with the NFL Alumni Health marketing platform, gives Corexa Pharmacy a unique customer acquisition channel to dispense FDA-approved GLP-1 medications and the medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies
• Exclusive license to the REBOOT GLP-1 patient management platform and intellectual property creates moat to scale customer acquisition and increase long-term customer value through patented, AI-assisted patient management services
• Corexa Pharmacy launch of compounded peptides under FDA's Enforcement Discretion Policy adds an incremental revenue opportunity
• MOU with HMO to deploy the Health Lives Here mobile app to 25,000+ members provides institutional customer to optimize PMPM model institutional customers
• Acquisition of Helomics cancer diagnostics laboratory, coupled with Humana Medicaid coverage for proprietary ChemoFx® Assay, adds incremental proprietary revenue stream, in addition to traditional lab services revenue, and opens cancer pharmaceuticals market for Corexa Pharmacy
• Company regains full compliance with Nasdaq listing standards

• NFL Alumni Health to support HMO member engagement
• Relationship centers on improving member GLP-1 related outcomes through use of the Health Lives Here app and easy access to telehealth, pharmacy and lab testing services
• Aim is to reduce hospitalizations and adverse drug events for patients on GLP-1 therapy

• Being marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmacies
• To be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026
• Program will aim to bring best practices for respiratory season to community pharmacies
• Nuvaxovid COVID vaccine (protein-based / non-mRNA) prioritized for campaign rollout
• Improve telehealth availability in the pharmacy through Health Lives Here mobile app
• Tests to include COVID neutralizing antibodies, antibodies & acute respiratory infections
• Long COVID-related biomarkers (cardiovascular, incl microclots; immune; metabolic; etc)
• Immune profiling for other circulating respiratory diseases (influence, RSV, strep, others)
• Improve access to FDA-approved antivirals
• Pharmacist education on Tollo Health medical foods and dietary supplements

• Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035
• Customer Acquisition Plan Leverages Existing Relationship with NFL Alumni Health
• Final Guidance issued by FDA Provides Roadmap for Prescription Drug Proprietary Health Lives Here^™ App and DelivMeds^® Software
• Network of 6,500 Pharmacies to Provide Nationwide Physical Healthcare Outlet

Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market

Platform to be integrated into Health Lives Here app as a subscription offering

Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx^® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers

Humana adds ChemoFx^® to its Medicaid Pharmacogenomics Testing coverage policy

Healthcare IT Company and its Subsidiary Undertake Action Following US Government's Updated Nomenclature

September 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launches

Healthcare IT Company and Nutritional Products Maker to Work with NFL Alumni Health to Drive Awareness of GLP-1 Telehealth and Pharmacy Services

Interim Co-CEO to Discuss Growing Patient Desire to Own Health Data

Updated Website Aligns with Pending Marketing Initiatives Following Recent Acquisition of Helomics CLIA-certified Laboratory and Litigation Settlement

Acquisition Provides Operational Capital to Drive Health Lives Here Campaign and Expand Services into Cancer Management

Leading Healthcare IT Company and Former NFL Players Will Work Together to Provide Rural Communities Access to Telehealth and Pharmacy-based Services Through Health Lives Here Mobile App

This version includes the correct image.

• Revenues grew 14% reaching $1.779M in Q2/26, beating management projections

• Corporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, which led to stock symbol change from ‘WGRX' to ‘MEDS' on NASDAQ Capital Markets

• $6.5 million new funding in June 2026 provided capital to support corporate turnaround

• Pending transaction with Datavault AI, EOS Technology Holdings, Scilex Holdings and HealthBridge Associates to consolidate patent protected blockchain, biometrics and pharmaceutical-adjunct products intellectual properties to deliver the "Health Lives Here" consumer app, in partnership with NFL Alumni Health (NFLAH), to deliver an effective healthcare experience to patients in rural communities via local independent pharmacies

• 1:50 reverse split in May 2026 implemented to partially address NASDAQ delisting risk

• Holders of 1,533,930 common shares, representing ~49% of shares outstanding, have entered into lock-up agreements for at least an additional ninety (90) days

• Dream Bowl Meme Coin I token distribution Payment Date set as September 9, 2026 with ratio of 50 tokens per common share owned as of end of business August 7, 2026

• KareRx joint venture added Electronic Benefits Verification (EBV) and access to 200,000 patient lives that began to provide material revenue to rebranded Corexa Pharmacy

• Neuritek Therapeutics, Inc. pending acquisition was terminated in May 2026

Initiative with NFL Alumni Health is aimed at improving rural healthcare access by powering Health Lives Here consumer app that integrates Einstein AI with independent pharmacies and proprietary patient engagement tools

Data monetization and real-world asset tokenization technologies licensed into the DataMeds AI's EinsteinRX Platform

Healthcare data represents 30%+ of global data assets growing by 36% per annum; DVLT and MEDS patented technology platforms designed to value, score and monetize healthcare data

Trading under new symbol (NASDAQ: MEDS) completes corporate rebranding from prior corporate name Wellgistics Health (NASDAQ: WGRX)

Experienced Healthcare Information Technology Specialist Joins Leading Pharmaceutical IT Company

• Executives exercise previously issued warrants to acquire 200,000 common shares

• Shares issued in connection with exercise added to existing lock-up agreements

• Name reflects vertically-aligned healthcare ecosystem business model integrating data captured via telemedicine, online pharmacy, lab tests and wearables to perfect patients' digital health twins in the Health Lives Here app designed to influence/optimize behavior

• EinsteinRx AI^™ capabilities expanding into medical, laboratory and wearables fields

• Pharmacy and Pharmacy Services division being rebranded as Corexa Health^™

• Company positioned to empower patients to seize ownership of their health data with blockchain-enabled data management to control data and participate in its monetization

• (1) 2,647,198 common shares outstanding, with (2) 1,333,930 of those shares locked up for at least ninety (90) days from today, and (3) 919,465 common shares deposited in DTCC, leaving (4) 80,628 cash warrants with fixed $35.00 exercise price representing only other securities currently eligible for deposit into DTCC for free trading shares

• Focus is on closing DelivMeds AI transaction, driving pharmacy revenue growth and supporting PharmacyChain™, Medical Drones and Health Lives Here progress

• Recent capital raise provides capital into late 2026, including meeting criteria for DelivMeds AI transaction funding closing condition

• Recent capital raise and debt restructuring preclude the Company from issuing shares for capital raising purposes until the earlier of seven (7) months from the transaction date and thirty (30) days after effectiveness of the resale registration statement covering the underlying securities.

• Recent lock-up agreement to limit shares available for sale into the market

• Exercise of warrants embedded in recent financing would provide funding through 2029

• Holders of 1,333,930 common shares agree to minimum 90-day lock-up agreement

• New oversubscribed $21 million convertible debt instrument ("New Debt") refinances all outstanding convertible debt, provides $6.5 million in new capital for working capital and general corporate purposes does not accrue interest and converts into common shares at $6.00 per share

• Automatic Exchange provision automatically converts the New Debt into Preferred Stock upon the effectiveness of a registration statement and attainment of shareholder approval for the creation of Preferred Stock

• The class of Preferred Stock that the New Convertible Debt exchanges into (the "Funding Preferred") converts into common shares at $50.00 per share

• New funds raised satisfy capital raising closing condition from Fully Binding Term Sheet with Datavault AI, EOS Technology Holdings, Scilex Pharma and HealthBridge Advisors

• 1-for-50 reverse split of common shares outstanding now complete

• 2,513,425 common shares now outstanding

• A new CUSIP was issued in connection with reverse split

This Press Release updates the information from the previous release.

Why Vertical Integration and Blockchain Will Define the Next Era of Healthcare

Why Vertical Integration and Blockchain Will Define the Next Era of Healthcare

• Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited results

• Q1-26 focus on optimization of Wellgistics Pharmacy revenue growth and capabilities positions Company to integrate emerging licensed PharmacyChain™ pharmacy data tokenization technology into pharmacy dispensing AI hub EinsteinRx™

• Kare Pharmtech joint venture expands the Company's telepharmacy and direct-to-patient capabilities, providing immediate access to 200,000+ patient lives

• Strategic partnership with Tollo Health provides access to proprietary pharmaceutical-adjunct medical foods & dietary supplements, telemedicine and mental health AI coaching & regimen compliance tools via "Health Lives Here" app that is targeted to launch in August 2026 following the reveal with NFL Alumni Health at 2026 NFL Draft in Pittsburgh

• The Company is in advanced discussions with Datavault AI regarding a binding term sheet to expand the scope of the PharmacyChain™ license to include Health-as-a-Service (HaaS) capabilities

• Company has terminated previously announced non-binding letters of intent with Neuritek and WellCare and does not intend to proceed with those transactions

Highlights:

• WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutions

• Combination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmacies

• Proposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordination

• Proposed transaction valued at approximately $15 million

• Strategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providers

Highlights:

• According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹

• Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructure

• Approximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providers

• Wellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiatives

• Participating pharmacists expected to gain access to new clinical service revenue opportunities

• Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations

• Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization

• Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks